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ABSTRACT
Diffuse alveolar hemorrhage (DAH) is a noninfectious pulmonary complication of hematopoietic stem cell
transplantation (HSCT) with unclear pathogenesis and treatment. We reviewed prospectively collected data on
1919 consecutive transplants performed between 1995 and 2004 and compared patients with DAH and
infection-associated alveolar hemorrhage (IAH) who presented with similar symptoms of hypoxemia, pulmo-
nary infiltrates, and progressively bloody alveolar lavage but also had microorganisms isolated from blood,
bronchoalveolar lavage, or tracheal aspirate within 1 week of alveolar hemorrhage. Overall, 116 patients had
alveolar hemorrhage (45 with DAH, 71 with IAH). Older age, allogeneic donor source, myeloablative condi-
tioning regimen, and acute severe graft-versus-host disease (GVHD) were independently predictive of an
increased risk of post-HSCT alveolar hemorrhage. The DAH and IAH groups were comparable except for a
higher proportion of patients receiving umbilical cord blood as a donor source and total-body irradiation–
containing conditioning in the IAH group. The probability of 60-day survival from onset of hemorrhage was
16% (95% CI, 6%–26%) for the DAH and 32% (95% CI, 21%–43%) for the IAH group (P  .08). All except
20 patients were treated with a standard regimen of high-dose corticosteroids. Patients who received corti-
costeroids had 60-day survival of 26% (95% CI, 18%–34%), compared with 25% (95% CI, 6%–44%) for those
who did not (P  .28). The pathogenesis of alveolar hemorrhage after HSCT is multifactorial, and we propose
that IAH and DAH in HSCT recipients are related clinical syndromes with similar clinical presentation, risks,
and associated high mortality.
© 2006 American Society for Blood and Marrow Transplantation
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cNTRODUCTION
Alveolar hemorrhage, a clinical syndrome charac-
erized by the acute onset of alveolar inﬁltrates and
ypoxemia, is diagnosed by the presence of progres-
ively bloodier alveolar lavage on bronchoscopy [1,2].
lveolar hemorrhage occurring in hematopoietic stem
ell transplantation (HSCT) recipients in the absence
f an identiﬁable infection is called diffuse alveolar
emorrhage (DAH). The reported incidence of DAH
fter HSCT ranges from 1% to 5% in autologous i
038raft recipients and from 3% to 7% in allogeneic graft
ecipients [3-5]. The majority of patients with DAH
evelop severe respiratory failure, with mortality rates
f 70% or higher [3-7].
DAH originates from the pulmonary microvascu-
ature and is postulated to be a response to alveolar
njury; however, the exact etiology of DAH in HSCT
emains unknown. Vascular damage and inﬂammation
rom chemotherapy and radiation therapy used in the
onditioning regimen, and immune-mediated events,
ncluding graft-versus-host disease (GVHD), have
b
p
d
a
a
s
q
a
d
h
r
b
p
c
a
h
t
a
f
d
i
M
P
o
D
i
u
n
g
h
D
m
i
w
c
p
c
t
h
t
n
a
i
1
i
h
h
p
i
n
6
p
c
s
w
d
o
S
t
i
d
f
c
c
G
b
f
w
b
f
w
T
i
ﬂ
f
T
o
c
ﬂ
t
l
i
a
s
i
a
d
f
a
S
a
n
d
p
o
e
t
A
m
Alveolar Hemorrhage in Stem Cell Transplantation 1039een implicated in its pathogenesis [3,5,8,9]. Although
ulmonary and systemic infections cause alveolar
amage through similar mechanisms [10], infection-
ssociated alveolar hemorrhage (IAH) has tradition-
lly been excluded from analyses of DAH. Autopsy
tudies have shown that pulmonary infections are fre-
uently underdiagnosed in HSCT recipients [11-13],
nd hence patients with alveolar hemorrhage and un-
erlying undetected infections can be misclassiﬁed as
aving DAH. We hypothesized that alveolar hemor-
hage after HSCT is multifactorial in origin and that
oth infectious and noninfectious etiologies play im-
ortant roles in its pathogenesis. Consequently, we
ompared the clinical courses and outcomes of DAH
nd IAH.
Risk factors for developing alveolar hemorrhage
ave not been studied; the literature focuses largely on
he incidence and outcomes of alveolar hemorrhage
fter HSCT. Therefore, we also conducted a risk
actor analysis to deﬁne factors associated with the
evelopment of alveolar hemorrhage in HSCT recip-
ents.
ATERIALS AND METHODS
atients
Prospectively collected data from the University
f Minnesota Bone Marrow Transplant Biostatistics
atabase was reviewed for pulmonary complications
n 1919 patients who underwent HSCT between Jan-
ary 1995 and December 2004. One or more pulmo-
ary complications occurred in 1122 patients under-
oing HSCT over this 10-year period; pulmonary
emorrhage as was identiﬁed in 229 of these patients.
atabase information for the 229 patients was supple-
ented by a review of medical records.
Alveolar hemorrhage was diagnosed by strict clin-
cal criteria, which included acute onset of hypoxemia
ith presence of diffuse pulmonary inﬁltrates on a
hest X-ray or computed tomography scan and the
resence of progressively bloodier return on bron-
hoalveolar lavage (BAL). In the absence of any iden-
iﬁable infection within 1 week of diagnosis of alveolar
emorrhage, the diagnosis of DAH was made. Pa-
ients who presented with similar hypoxemia, pulmo-
ary inﬁltratesm and progressively bloodier BAL but
lso had microorganisms (excluding Aspergillus spp)
solated from blood, BAL, or tracheal aspirate within
week of alveolar hemorrhage were classiﬁed as hav-
ng IAH.
Of the 229 patients with suspected pulmonary
emorrhage, 116 met the study criteria for alveolar
emorrhage. The 113 excluded cases consisted of 57
atients diagnosed only by clinical or radiologic ﬁnd-
ngs without concurrent BAL, 31 patients with diag-
osis made on autopsy without antemortem BAL, and ﬁpatients with invasive aspergillosis. Also, among the
atients who underwent bronchoscopy, 16 were ex-
luded because the BAL ﬁndings did not meet our
tudy deﬁnition of alveolar hemorrhage, and another 3
ere excluded because the BAL was negative and the
iagnosis was made by transbronchial lung biopsy
nly.
tudy Methods
BAL was performed in all patients during ﬁberop-
ic bronchoscopy. Aliquots of saline were successively
nstilled and aspirated and then visually examined to
etect the presence of alveolar hemorrhage. BAL ﬂuid
or all patients was submitted for cytological and mi-
robiological examination. Cytological evaluation in-
luded specimen review using potassium hydroxide,
iemsa, and Papanicolaou stains. Appropriate micro-
iological and cytological examinations for bacteria,
ungi, mycobacteria, Pneumocystis carinii, and viruses
ere also performed for all patients. In some intu-
ated patients, in addition to BAL, tracheal aspirates
or microbiological examination were also obtained
ithin 1 week of diagnosis of alveolar hemorrhage.
hese specimens were submitted for similar cytolog-
cal and microbiological examinations as for BAL
uid. Blood was also routinely sent for bacterial and
ungal cultures.
reatment of Alveolar Hemorrhage
Supportive measures for the management of alve-
lar hemorrhage included correction of platelet and
oagulation abnormalities, careful maintenance of
uid and electrolyte balance, and aggressive ventila-
ory and oxygen support. All patients received prophy-
actic and empiric antimicrobial agents as clinically
ndicated; patients with IAH also received appropriate
ntibiotics to treat the underlying infection. Cortico-
teroids, if administered, consisted of a standard reg-
men of high-dose methylprednisolone, 500 mg twice
day for 3 days, followed by 250 mg twice a day for 3
ays, 125 mg twice a day for 3 days, 60 mg twice a day
or 3 days, and then 60 mg once a day tapered off over
2-month period.
tudy Definitions and Statistical Analysis
The time of neutrophil engraftment was deﬁned
s the ﬁrst of 3 consecutive days with an absolute
eutrophil count  0.5  109/L. The period within 5
ays of neutrophil engraftment was deﬁned as the
eriengraftment period. For this study, onset of hem-
rrhage within 30 days of HSCT was classiﬁed as
arly alveolar hemorrhage, whereas that occurring af-
er 30 days was classiﬁed as late alveolar hemorrhage.
second hemorrhage occurring in the same patient
ore than 30 days after the initial episode was classi-
ed as recurrent alveolar hemorrhage; hemorrhage
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N.S. Majhail et al.1040ecurring within 30 days was considered part of the
nitial episode.
For risk factor analysis, the source cohort included
ll 1919 patients who received HSCT at the Univer-
ity of Minnesota between 1995 and 2004. However,
atients who were listed as having “pulmonary hem-
rrhage” in the database but did not meet our study
eﬁnition of alveolar hemorrhage (n  113) were
xcluded. The following exposures were investigated
or association with risk of developing alveolar hem-
rrhage after HSCT using Cox regression analysis
14] in the remaining 1806 patients: age at transplan-
ation, sex, donor source (autologous vs allogeneic),
ntensity of conditioning regimen (myeloablative vs
educed intensity), use of total-body irradiation (TBI)
r busulfan in the conditioning regimen, and history
f severe (grade 3 or 4) acute GVHD (time-dependent
nalysis). Risk factor analysis using this model was also
erformed separately for DAH and IAH.
Among the smaller combined group with DAH or
AH, Cox regression analysis was also performed to
dentify factors inﬂuencing survival beyond 60 days of
he onset of alveolar hemorrhage. The following po-
ential prognostic variables were considered in the
orward-stepwise regression model: age at HSCT, sex,
resence of infection, donor source, intensity of con-
itioning regimen, use of TBI, use of busulfan, time to
emorrhage from HSCT, time between hemorrhage
nd engraftment, absolute neutrophil count at the
ime of hemorrhage, presence of acute GVHD (time-
ependent analysis), and corticosteroid use.
The cumulative incidence of alveolar hemorrhage
as calculated by treating deaths from other causes as
ompeting risks [15]. Comparison of patient charac-
eristics was done using the 2 test or Fisher’s exact
est for categorical variables and Wilcoxon’s rank-sum
est for continuous variables [16]. The probability of
verall survival at 60 days from the onset of DAH was
alculated using the Kaplan-Meier method [17], with
5% conﬁdence intervals (CIs) derived from the stan-
ard errors; survival curves were compared using the
og-rank test. All P values reported are 2-sided, and a
values .05 were considered statistically signiﬁcant.
ata analysis was performed using SAS software, ver-
ion 8.0 (SAS Institute, Cary, NC). The analysis was
erformed in December 2005.
ESULTS
atient Characteristics
Table 1 details patient and transplant characteris-
ics for the 116 cases of alveolar hemorrhage. The
edian age at onset of alveolar hemorrhage was 40
ears (range, 0.6–71 years). Most of the patients
89%) received an allogeneic HSCT. The indications
or HSCT included acute myeloid leukemia (n  29), 4hronic myeloid leukemia (n  23), non-Hodgkin’s
ymphoma (n  16), myelodysplastic and myelopro-
iferative disorders (n  12), acute lymphocytic leuke-
ia (n  9), Hodgkin’s lymphoma (n  8), Fanconi’s
nemia (n 7), chronic lymphocytic leukemia (n 2),
ultiple myeloma (n  1) and other metabolic disor-
ers (n  9). The median time to onset of alveolar
emorrhage from HSCT was 28 days (range, 3
ays–26 months); 55 (47%) patients had late-onset
lveolar hemorrhage. Severe hemorrhage requiring
ntubation and ventilatory support occurred in 85% of
he patients.
lveolar Hemorrhage: Incidence
A total of 114 cases of alveolar hemorrhage oc-
urred in the 1919 patients who underwent transplan-
ation between 1995 and 2004. (Two patients who
nderwent transplantation in 2004 but developed
emorrhage in 2005 were excluded from the incidence
nalysis.) Overall, the cumulative incidence of alveolar
emorrhage at 180 days after HSCT was 5% (95%
I, 4%–6%). The 180-day cumulative incidence was
% (95% CI, 1%–3%) for DAH and 4% (95% CI,
%–5%) for IAH (Figure 1A). According to donor
ource, the 180-day cumulative incidence of alveolar
emorrhage was 2% (95% CI, 1%–3%) for autolo-
ous donor, 8% (95% CI, 6%–10%) for matched
ibling donor, 6% (95% CI, 4%–8%) for matched
nrelated donor, and 7% (95% CI, 5%–9%) for un-
elated umbilical cord blood HSCT (P  .01 for all
airwise comparisons between autologous and each
llogeneic donor source) (Figure 1B).
lveolar Hemorrhage: DAH versus IAH
A total of 45 patients met the strict study deﬁni-
ion of DAH, and 71 patients were diagnosed with
AH. The 2 groups were comparable except for a
igher proportion of patients receiving unrelated um-
ilical cord blood transplant (30% vs 11%; P  .04)
nd TBI-containing conditioning regimens (90% vs
6%; P .04) in the IAH cohort (Table 1). There was
o signiﬁcant difference in time to hemorrhage from
SCT, time to neutrophil engraftment, time between
emorrhage and neutrophil engraftment, absolute
eutrophil count at the onset of hemorrhage, and rate
f acute GVHD between the 2 groups.
Microorganisms were isolated from BAL or tra-
heal aspirate only in 50 patients, from blood only in
2 patients, and from both respiratory and blood spec-
mens in 9 patients; 10 patients had polymicrobial
nfection. A total of 67 microorganisms were identi-
ed in 59 patients with positive BAL or tracheal aspi-
ate, including coagulase-negative Staphylococcus spp.
n  18), Enterococcus spp. (n  12), cytomegalovirus
n 8), Candida albicans (n 6), Candida glabrata (n
), Pseudomonas aeruginosa (n  4), Staphylococcus aureus
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Alveolar Hemorrhage in Stem Cell Transplantation 1041n 4), respiratory syncytial virus (n 3), Enterobacter
loacae (n  2), Streptococcus viridans (n  2), adenovi-
us (n  1), Hemophilus inﬂuenzae (n  1), Saccharo-
yces cerevisiae (n 1), and Pneumocystis carinii (n 1).
mong the 21 patients with positive blood cultures, 22
rganisms were isolated, including coagulase-negative
taphylococcus spp. (n  9), Enterococcus spp. (n  4),
able 1. Patient and Transplant Characteristics (All Patients and DAH
Characteristics
ge
Median (years)
Range (years)
ex
Male
Female
ime to hemorrhage from HSCT
Median (days)
Range (days)
ype of HSCT
Autologous
MSD
MUD
UCB
tem cell source
BM
PBSC
UCB
onditioning regimen
Busulfan
No busulfan
onditioning regimen
TBI
No TBI
onditioning regimen
Myeloablative
RIC
cute GVHD
Yes
No
bsolute neutrophil count at time of hemorrhage ( 109/L)
Median
Range
ime to engraftment
Median (days)
Range (days)
ime between hemorrhage and engraftment†
Pre-engraftment
Periengraftment
Postengraftment
se of corticosteroids
Yes
No
eed for intubation and ventilatory support
Yes
No
SD, allogeneic matched sibling donor; MUD, allogeneic matched
marrow; PBSC, peripheral blood stem cell; RIC, reduced-inten
P value for comparison between DAH and IAH.
Pre-engraftment, hemorrhage more than 5 days before engraftm
graftment, hemorrhage more than 5 days after engraftment.seudomonas aeruginosa (n  4), Candida krusei (n  1), rorynebacterium spp. (n  1), Escherichia coli (n  1),
taphylococcus aureus (n  1), and Streptococcus viridans
n  1).
Survival at 60 days from the onset of hemorrhage
as 16% (95% CI, 6%–26%) for the DAH group and
2% (95% CI, 21%–43%) for the IAH group (P 
08) (Figure 2A). Within the IAH group, patients with
H)
l Patients
 116) (%)
DAH
(n  45) (%)
IAH
(n  71) (%) P*
40 37 41 .51
0.6–71 0.6–71 0.6–63
70 (60) 25 (56) 45 (63) .40
46 (40) 20 (44) 26 (37)
28 21 31 .22
3–785 5–785 3–450
13 (11) 7 (16) 6 (8) .04
49 (42) 18 (40) 31 (44)
28 (24) 15 (33) 13 (18)
26 (23) 5 (11) 21 (30)
48 (41) 20 (44) 28 (39) .06
42 (36) 20 (44) 22 (31)
26 (23) 5 (11) 21 (30)
17 (15) 9 (20) 8 (11) .19
99 (85) 36 (80) 63 (89)
98 (84) 34 (76) 64 (90) .04
18 (16) 11 (24) 7 (10)
98 (84) 39 (87) 59 (83) .61
18 (16) 6 (13) 12 (17)
47 (41) 14 (31) 33 (46) .10
69 (59) 31 (69) 38 (54)
1.7 1.6 1.7 .50
0.1–39.1 <0.1–39.1 <0.1–29.9
17 15 18 .09
6–94 6–29 7–94
25 (21) 9 (20) 16 (22) .70
31 (27) 14 (31) 17 (24)
60 (52) 22 (49) 38 (54)
96 (83) 41 (91) 55 (78) .06
20 (17) 4 (9) 16 (22)
99 (85) 41 (91) 58 (82) .16
17 (15) 4 (9) 13 (18)
ted donor; UCB, unrelated umbilical cord blood donor; BM, bone
ditioning.
riengraftment, hemorrhage within 5 days of engraftment; posten-vs IA
Al
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<
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ent; peespiratory infections had a 60-day survival of 34%
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N.S. Majhail et al.104295% CI, 22%–46%) compared to 25% (95% CI,
–53%) in those with positive blood cultures only
P  .20). The 60-day survival did not differ signiﬁ-
antly among patients with bacterial infections (33%;
5% CI, 20%–46%), patients with fungal infections
38%; (95% CI, 4%–72%), and patients with viral
nfections (36%; 95% CI, 8%–64%) (P  .87). Three
atients with polymicrobial infections due to a com-
ination of bacteria, fungi, and viruses were excluded
rom this analysis.
urvival and Prognostic Factors
Overall, 86 patients (74%) died within 60 days and
2 patients (79%) died within 180 days from the onset
f alveolar hemorrhage; the median time from onset
f hemorrhage to death was 15 days (range, 1–166
ays). The probability of overall survival at 60 days
rom the onset of alveolar hemorrhage for the whole
ohort was 26% (95% CI, 18%–34%) (Figure 3).
Of the 24 patients surviving beyond 180 days of
lveolar hemorrhage, 13 are still alive with a median
ollow-up of 50 months (range, 12–100 months). The
auses of death in the remaining 11 patients were
igure 1. Cumulative incidence of alveolar hemorrhage accord-
ng to (A) type of hemorrhage (DAH vs IAH) and (B) donor
ource (autologous [Auto] vs matched sibling donor [MSD] vs
atched unrelated donor [MUD] vs unrelated umbilical cord
lood [UCB]).elapse of primary disease (n  6), chronic GVHD en  3), and infection (n  2). None of these 24
atients experienced any long-term major pulmonary
equelae. Results of pulmonary function tests done
retransplantation and beyond 6 months after alveolar
emorrhage were available for comparison in 7 pa-
ients. The mean ( standard deviation) drop in
orced expiratory volume in 1 second was 1%  13%
P  .25), that of forced vital capacity was 6%  23%
P .45), and that of diffusing capacity of the lung for
O2 was 32%  22% (P  .11).
Univariate analysis found that early-onset alveolar
emorrhage and hemorrhage occurring in the perien-
raftment period were associated with a favorable out-
ome (Table 2). Patients with early-onset alveolar
emorrhage had 60-day survival of 34% (95% CI,
2%–46%), compared with 16% (95% CI, 6%–26%)
or patients with late-onset hemorrhage (P  .02)
Figure 2B). The 60-day survival for patients with
emorrhage occurring in the periengraftment period
as 48% (95% CI, 31%–65%), compared with 24%
95% CI, 7%–41%) for those with onset before 5 days
f engraftment and 15% (95% CI, 6%–24%) for those
ith onset after 5 days of engraftment (P  .01)
Figure 2C). Time between hemorrhage and engraft-
ent was the only factor independently predictive of
verall survival in Cox regression analysis; onset of
lveolar hemorrhage in the periengraftment period
orrelated with a better 60-day survival (relative risk,
.5; 95% CI, 0.3–0.8; P  .01).
isk Factors for Development of
lveolar Hemorrhage
The results of Cox regression analysis for variables
ssociated with increased risk of alveolar hemorrhage
fter HSCT are given in Table 3. Older age, alloge-
eic donor source, myeloablative conditioning regi-
en, and severe acute GVHD were independently
ssociated with increased incidence of post-HSCT
lveolar hemorrhage.
fficacy of Corticosteroids
Overall, 96 (83%) patients were treated with a
tandardized regimen of intravenous high-dose meth-
lprednisolone. A higher proportion of patients re-
eived this regimen in the DAH group than in the
AH group (91% vs 71%; P  .06). The 60-day
urvival from the onset of alveolar hemorrhage was
6% (95% CI, 18%–34%) for patients who received
igh-dose methylprednisolone, compared with 25%
95% CI, 6%–44%) for those who did not (P  .28)
Figure 2D). Furthermore, use of high-dose methyl-
rednisolone was not associated with a signiﬁcant dif-
erence in the 60-day survival in the DAH, IAH, and
arly-onset hemorrhage subgroups.
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Alveolar Hemorrhage in Stem Cell Transplantation 1043ISCUSSION
Pulmonary complications are among the most
ommon causes of morbidity and mortality in HSCT
ecipients. Alveolar hemorrhage is a posttransplanta-
igure 2. Survival at 60 days from the onset of alveolar hemorrhag
0 days) hemorrhage. (C) Time between hemorrhage and engraftm
ithin 5 days of engraftment (periengraftment) versus  5 days aft
igure 3. Overall survival from the onset of alveolar hemorrhage
nall patients).ion pulmonary complication associated with a partic-
larly fulminant clinical course and high mortality.
The etiopathogenesis of alveolar hemorrhage in
he post-HSCT setting remains largely unknown; the
urrent paradigm is based on DAH observed in the
ontransplantation setting. The prototypical disor-
ers for nontransplantation DAH are the systemic
asculitides and collagen vascular diseases, where al-
eolar injury and capillaritis due to various immune-
ediated mechanisms leads to damage to the alveolar
icrocirculation [18]. However, alveolar hemorrhage
n the posttransplantation setting is multifactorial in
rigin. Besides similar immune-mediated injury, other
utative mechanisms of small-vessel damage after
SCT include vasculopathy due to high-dose chemo-
herapy, radiation therapy, or GVHD [3,5,9]; throm-
otic microangiopathy [19]; effect of inﬂammatory
ediators [3,20]; and alterations in cardiopulmonary
emodynamics in the peritransplantation period. In-
ections frequently occur in the posttransplantation
eriod and are potentially signiﬁcant contributors to
he pathogenesis of this syndrome. Current tech-
AH versus IAH. (B) Early-onset ( 30 days) versus late-onset (
emorrhage  5 days before engraftment (pre-engraftment) versus
aftment (postengraftment). (D) Use of high-dose corticosteroids.e. (A) D
ent (hiques of BAL may miss certain infections; autopsy
s
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N.S. Majhail et al.1044tudies have shown high rates of occult pulmonary
nfections in HSCT recipients [11-13]. Emerging
athogens, such as human herpesvirus-6 (HHV-6),
hich are not regularly sought in the BAL ﬂuid, might
lso contribute to its development. The contemporary
iterature on alveolar hemorrhage after HSCT has
ocused primarily on DAH and has excluded patients
ith underlying infections. We found no differences
etween the clinical syndromes of DAH and IAH with
espect to presentation, response to corticosteroids,
nd overall outcome. We suggest that clinically dis-
inguishing DAH and IAH in HSCT recipients is
ifﬁcult. The approach to posttransplantation alveolar
emorrhage needs to reﬂect this entity’s diverse and
omplex pathogenesis.
Coagulase-negative Staphylococcus spp. was the
ost commonly isolated organism in the IAH group.
stablishing the pathogenicity of this less virulent
rganism in HSCT recipients can be a challenge;
owever, we used strict criteria for diagnosing infec-
ions, and it is unlikely that this organism’s isolation
rom BAL ﬂuid represented mere contamination. Fur-
hermore, even colonization of the deep bronchial
irways and alveolar epithelium by such microbes
able 2. Univariate Analysis of Factors Inﬂuencing Survival at 60 Da
Factor
A
verall 2
ge at HSCT
<45 years 2
>45 years 3
onor type
Autologous 2
Allogeneic 2
onor source
Autologous 2
Matched related donor 2
Matched unrelated donor 2
Umbilical cord blood 2
ime to hemorrhage from HSCT
Early onset (<30 days) 3
Late onset (>30 days) 1
ime between hemorrhage and engraftment‡
<5 days 2
5 days 4
>5 days 1
onditioning regimen§
Myeloablative 2
Reduced-intensity 2
teroids
Received 2
Not received 2
P  .05 for within-group comparison.
P  .01 for within-group comparison.
5 days, hemorrhage occurring pre-engraftment; 5 days, he
postengraftment.
Allogeneic HSCT only (n  103).ould play a role in the development of this syndrome. ae speculate that microorganisms could potentiate
lveolar injury caused by chemotherapy, radiation
herapy, and GVHD. In addition, they could indepen-
ently cause local inﬂammation and increase alveolar
ermeability. The heterogeneity of microorganisms
ecovered in the IAH group, particularly from pulmo-
ary specimens, points to the difﬁculty in attributing
osttransplantation alveolar hemorrhage to infection
r DAH. These observations again highlight the over-
ap between DAH and IAH.
Factors independently predictive of increased in-
idence of alveolar hemorrhage after HSCT were
lder age, allogeneic donor source, use of myeloabla-
ive conditioning, and presence of severe acute
VHD. Each of these risk factors has the potential to
ither cause lung injury or make the lungs more sus-
eptible to other insults. In addition, infections (par-
icularly respiratory infections) may be important con-
ributing factors to the risk of posttransplantation
lveolar hemorrhage.
In our study, patients with early-onset alveolar
emorrhage, particularly hemorrhage in the perien-
raftment period, had better survival. In a retrospec-
ive study of 48 patients, Afessa et al [21] also found an
the Onset of Alveolar Hemorrhage
Percent 60-day Survival (95% CI)
ents
16)
DAH
(n  45)
IAH
(n  71)
34) 16 (6–26) 32 (21–43)
34) 17 (3–21) 28 (15–41)
43) 13 (0–29) 39 (21–57)
6) 0 50 (10–90)
34) 18 (6–30) 31 (20–42)
6) 0 50 (10–90)
40) 22 (3–41) 32 (16–48)
6) 20 (0–40) 23 (0–46)
46) 0 33 (13–53)
46)* 18 (4–32) 46 (29–63)*
6)* 12 (0–27) 20 (7–33)*
1)† 0* 38 (14–62)*
65)† 36 (11–61)* 59 (36–82)*
4)† 9 (0–21)* 18 (6–30)*
35) 22 (8–36) 28 (16–40)
9) 0 42 (14–70)
34) 15 (4–26) 35 (22–48)
6) 25 (0–67) 25 (4–46)
ge occurring periengraftment; 5 days, hemorrhage occurringys from
ll Pati
(n  1
6 (18–
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0 (17–
3 (0–4
6 (18–
3 (0–4
8 (16–
1 (6–3
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Alveolar Hemorrhage in Stem Cell Transplantation 1045ality. The reason for this observation is unclear; how-
ver, it can be speculated that the more favorable
utcome in this cohort of patients might be related to
he transient nature of periengraftment “cytokine
torm” occurring due to release of inﬂammatory me-
iators from recovering neutrophils, compared with
ther mechanisms of alveolar hemorrhage in which
lveolar injury tends to be more sustained.
Because inﬂammation is thought to play a role in
he pathogenesis of post-HSCT DAH, high-dose cor-
icosteroids have been widely used for its treatment.
owever, their use originates from a few case reports
nd small retrospective series [6,22,23], and there are
o well-designed clinical trials investigating their role
n this disorder. The use of high-dose corticosteroids
as not altered the poor outcome associated with this
yndrome, and mortality rates remain unchanged at
0%–100% [4,6,7,24,25]. The overall mortality rate
t 60 days from the onset of hemorrhage was 74% in
ur study and was unaffected by the use of corticoste-
oids, for both DAH and IAH. However, although all
f the patients in our cohort received a standard reg-
men of high-dose corticosteroids, the overall beneﬁt
f this therapy needs to be interpreted cautiously in
iew of the retrospective nature of our analysis.
There remains an urgent need for newer agents to
reat posttransplantation alveolar hemorrhage. There
re case reports describing the use of recombinant
actor VIIa for the management of post-HSCT DAH
26-28]; however, limited and mostly anecdotal expe-
ience suggest that it should be used cautiously. A
etter understanding of the pathogenetic mechanisms of
able 3. Multivariate Analysis of Factors Associated with an Increased
isk of Alveolar Hemorrhage, DAH and IAH Following HSCT
Variable All Patients DAH IAH
ge (per decade) 1.4 (1.2–1.6) 1.2 (1.1–1.6) 1.5 (1.3–1.7)
p < 0.01 p < 0.01 p < 0.01
onor type
Allogeneic 1.0 1.0 1.0
Autologous 0.2 (0.1–0.3) 0.2 (0.1–0.6) 0.1 (0.04–0.3)
p < 0.01 p < 0.01 p < 0.01
onditioning
regimen1
Myeloablative 1.0 1.0 1.0
Reduced-intensity 0.5 (0.3–0.9) 0.6 (0.2–1.5) 0.5 (0.2–1.0)
p  0.03 p  0.24 p  0.05
evere acute
GVHD1
Absent 1.0 1.0 1.0
Present 2.5 (1.3–4.8) 1.9 (0.6–6.6) 2.9 (1.4–6.1)
p < 0.01 p  0.29 p < 0.01
ox regression analysis on incidence of hemorrhage was performed
testing the following variables: age at transplant, gender, donor
source, intensity of conditioning regimen, use of total-body
irradiation or busulfan in conditioning, and time dependent
severe acute GVHD.
Allogenic HSCT only.ransplantation-associated alveolar hemorrhage couldead to development of more effective therapies. Because
ytokine release during engraftment and the presence of
irway inﬂammation are postulated mechanisms for this
yndrome, management with cytokine antagonists (eg,
nti–tumor necrosis factor, interleukin-1) and anti-in-
ammatory agents may merit formal study.
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